CG Oncology shares jump as cretostimogene cuts bladder cancer recurrence by 68%

CG Oncology (CGON) shares rose 14% after reporting that its immunotherapy, cretostimogene, reduced bladder cancer recurrence by 68% in a Phase III trial. The trial involved 367 patients and showed the treatment was well-tolerated. Median follow-up was 17 months.

Original reporting
Published Nov 17, 2026, 12:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CG Oncology shares jump as cretostimogene cuts bladder cancer recurrence by 68% — source image
Decision brief

The 30-second read

$CGONBullishMed
01

Why it matters

Meeting the Phase III primary endpoint with a large recurrence-risk reduction and a clean safety profile is a material de-risking event that can shift valuation expectations and increase interest from partners and future trial planners.

02

Market read

Traders can reassess probability-weighted outcomes for cretostimogene and the broader NMIBC immunotherapy landscape based on this pivotal readout.

03

What to watch

Trial design details (open-label, surveillance comparator) and the need for confirmatory endpoints or subgroup consistency could temper how far the market extrapolates from the primary endpoint.

Relevance 8/10Novelty 8/10Timing: reported Monday close after Phase III primary endpoint readout

Background

Cretostimogene grenadenorepvec is an oncolytic immunotherapy being evaluated in NMIBC; PIVOT-006 is a Phase III trial in intermediate-risk and high-grade Ta disease.

Company-level read

Ticker impact

$CGONBullishHigh confidence
Context

CG Oncology shares jumped after Phase III PIVOT-006 data showed cretostimogene reduced bladder cancer recurrence risk by 68% vs surveillance.

Expected impact

Likely upward pressure as traders price in improved clinical validation and potential path to approval, with volatility around follow-up details.

Evidence & confidence

The article reports primary endpoint achievement with a large relative risk reduction and favorable safety (no grade 3+ treatment-related AEs), which is a direct, decision-relevant catalyst for a clinical-stage biotech.

Market effects

Strengthens sentiment for oncolytic immunotherapy and NMIBC pipeline assets, potentially lifting peer group risk appetite.

Limited direct regional spillover beyond US-listed biotech sentiment.

Moderate global relevance as bladder cancer immunotherapy efficacy data can influence international development and partnering expectations.

Counterpoint

A 17-month median follow-up may be insufficient to fully characterize durability and long-term recurrence-free survival, so the initial reaction could fade if longer follow-up disappoints.

Key entities

  • CG Oncology

    Dallas-based company developing cretostimogene grenadenorepvec; reported Phase III PIVOT-006 primary endpoint success.

  • cretostimogene grenadenorepvec

    Oncolytic immunotherapy evaluated as adjuvant therapy after tumor resection in NMIBC.

  • PIVOT-006

    Phase III randomized open-label trial in intermediate-risk and high-grade Ta NMIBC; primary endpoint met.

Related articles

$CGONMed

CG Oncology Stock Falls 7% as RBC Downgrade Cools Rally After Bladder Cancer Drug Cuts Recurrence Risk by 68%

CG Oncology Inc. shares fell 7.53% on Tuesday, after a 14% rise on Monday following positive trial results for its bladder cancer treatment. RBC downgraded the stock to Sector Perform, citing regulatory path, despite raising its price target to $97. The Phase 3 trial showed a 68% reduction in cancer recurrence risk. Other analysts raised price targets, with JPMorgan at $113 and Truist at $100.

$CGONMed

Truist raises CG Oncology stock price target on trial results

Truist Securities raised its price target for CG Oncology (CGON) to $100 from $85, citing positive PIVOT-006 trial results. The stock is up 16.7% over the past week. Full data will be presented in December 2026, with FDA submissions expected in 2027. Analysts have revised earnings estimates upward, highlighting a multi-billion-dollar market opportunity.

$CGONMed

JPMorgan raises CG Oncology stock price target on trial data

JPMorgan raised its price target for CG Oncology (CGON) to $113 from $96, citing positive trial data and regulatory updates. The stock, currently at $84.78, has surged over 104% year-to-date. JPMorgan increased its success probability for Creto in bladder cancer treatments, projecting $1.2B and $1.0B in U.S. peak sales by 2037 for different settings. RBC Capital downgraded CGON to Sector Perform but raised its target to $97.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.